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Abstract
Introduction Heparan sulphate proteoglycan syndecan-1
modulates cell proliferation, adhesion, migration and
angiogenesis. It is a coreceptor for the hepatocyte growth factor
receptor c-met, and its coexpression with E-cadherin is
synchronously regulated during epithelial-mesenchymal
transition. In breast cancer, changes in the expression of
syndecan-1, E-cadherin and c-met correlate with poor
prognosis. In this study we evaluated whether coexpression of
these functionally linked prognostic markers constitutes an
expression signature in ductal carcinoma in situ (DCIS) of the
breast that may promote cell proliferation and
(lymph)angiogenesis.
Methods Expression of syndecan-1, E-cadherin and c-met was
detected immunohistochemically using a tissue microarray in
tumour specimens from 200 DCIS patients. Results were
correlated with the expression patterns of angiogenic and
lymphangiogenic markers. Coexpression of the three prognostic
markers was evaluated in human breast cancer cells by confocal
immunofluorescence microscopy and RT-PCR.
Results Coexpression and membrane colocalization of the
three markers was confirmed in MCF-7 cells. E-cadherin
expression decreased, and c-met expression increased
progressively in more aggressive cell lines. Tissue microarray
analysis revealed strong positive staining of tumour cells for
syndecan-1 in 72%, E-cadherin in 67.8% and c-met in 48.6% of
DCIS. E-cadherin expression was significantly associated with
c-met and syndecan-1. Expression of c-met and syndecan-1
was significantly more frequent in the subgroup of patients with
pure DCIS than in those with DCIS and a coexisting invasive
carcinoma. Levels of c-met and syndecan-1 expression were
associated with HER2 expression. Expression of c-met
significantly correlated with expression of endothelin A and B
receptors, vascular endothelial growth factor (VEGF)-A and
fibroblast growth factor receptor-1, whereas E-cadherin
expression correlated significantly with endothelin A receptor,
VEGF-A and VEGF-C staining.
Conclusion Syndecan-1, E-cadherin and c-met constitute a
marker signature associated with angiogenic and
lymphangiogenic factors in DCIS. This coexpression may reflect
a state of parallel activation of different signal transduction
pathways, promoting tumour cell proliferation and angiogenesis.
Our findings have implications for future therapeutic
approaches in terms of a multiple target approach, which may
be useful early in breast cancer progression.
Introduction
Syndecan-1/CD138 (Sdc1) is a cell surface heparan sulphate
proteoglycan that is highly expressed by epithelial and plasma
cells. Via its heparan sulphate chains, Sdc1 binds to a variety
of growth and angiogenic factors and acts as a classical core-
ceptor for growth factor receptors, thus promoting cell prolif-
eration [1]. Moreover, Sdc1 interacts with ligands in the
extracellular matrix and on cell surfaces, functioning as a cell
bFGF = basic fibroblast growth factor; DCIS = ductal breast carcinoma in situ; E-cad = E-cadherin; ER = oestrogen receptor; ET = endothelin; ETA/
BR = endothelin A/B receptor; FGFR = fibroblast growth factor receptor; HER = human epidermal growth factor receptor; HGF = hepatocyte growth 
factor; PBS = phosphate-buffered saline; PR = progesterone receptor; RT-PCR = reverse transcription polymerase chain reaction; Sdc1 = syndecan-
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adhesion molecule [1]. We recently showed that Sdc1 is a
modulator of proteolytic activities and chemokine functions in
vivo, which orchestrates leucocyte recruitment and tissue
remodelling during inflammation and wound repair [2-4]. In
Sdc1-deficient and Sdc1-overexpressing mouse models,
abnormal blood vessel formation is observed during wound
repair, confirming a role for Sdc1 as a regulator of angiogen-
esis in vivo [2,4]. Because the biological functions of Sdc1
potentially affect several steps in tumour progression, it is not
surprising that a prognostic value has been assigned to
changes in Sdc1 expression in several cancer types, including
colorectal, gastric, pancreatic, prostate, lung, endometrial and
ovarian cancers, as well as squamous cell carcinoma of the
head and neck (for review, see Yip and coworkers [5]). In
breast cancer, increased expression of Sdc1 correlates with
an unfavourable prognosis [6-8] and poor response to chem-
otherapy [9]. Of note, several proteins that are functionally
linked to Sdc1 by virtue of their biology are prognostic markers
on their own (Table 1). In multiple myeloma, Sdc1 mediates lig-
and binding and signalling through the hepatocyte growth fac-
tor (HGF) receptor tyrosine kinase c-met, resulting in
increased cancer cell proliferation [10].
Similar mechanisms may be of relevance in breast cancer,
because prognostic value has been established for c-met
expression in a number of clinical studies of breast cancer
patients (Table 1). Signal transduction mediated by c-met
modulates cell dissociation and motility, and protease overex-
pression [11,12]. Moreover, ribozyme targeting of c-met in
mammary cancer cells reduced mammary cancer and tumour-
associated angiogenesis in a xenograft model [12]. To mobi-
lize its full transforming potential in breast cancer, c-met
appears to depend on coactivating factors, such as overex-
pression of additional proto-oncogenes (MYC, RON), or β4
integrin activity [13-15]. Similarly, Sdc1 regulates αvβ3 integrin
activation and signalling in breast cancer cell lines [16,17].
Sdc1-integrin complexes may thus synergistically contribute
to tumour progression driven by c-met overexpression.
The calcium-dependent cell-cell adhesion molecule E-cad-
herin (E-cad) is an established prognostic marker in breast
cancer (Table 1). E-cad expression is irreversibly lost in inva-
sive lobular breast cancer, and this feature has been used by
pathologists to distinguish between ductal and lobular neopla-
sia [18-20]. Like Sdc1, E-cad is mostly present in epithelial
cells, and is required for maintaining the epitheloid phenotype
and inhibition of density-dependent cell growth [21]. Coordi-
nated regulation of E-cad and Sdc1 expression is seen during
development [22] and in mammary tumour cells subjected to
antisense RNA mediated downregulation of Sdc1 [23] or E-
cad [24], respectively. Sdc1 and E-cad colocalize and coim-
munoprecipitate with the transcriptional regulator β-catenin in
epithelial cells, suggesting both a functional and physical
association [25]. Of note, expression of Sdc1 is required for
proper development of a β-catenin responsive mammary epi-
thelial progenitor cell population, which appears to be the
mechanistic principle underlying resistance of Sdc1-deficient
mice to wnt-1 mediated breast cancer [5,26-28].
Table 1
Cancer-related functions and interrelation of Sdc1, c-met and E-cad
Marker Molecular characteristics Biological functions relevant 
to cancera
Clinical relevance to breast 
cancera
Relation to c-meta Relation to E-cada
Sdc1 Cell surface heparan 
sulphate proteoglycan
Cell and matrix receptor [1]
Coreceptor for chemokines, 
angiogenic and growth 
factors, and modulator of 
proteolytic activity [2-
4,16,57]
Positive correlation with poor 
prognosis and tumour 
angiogenesis [6-8,33]
Predictive factor in 
neoadjuvant chemotherapy 
[9]
Sdc1 is c-met co-receptor in 
multiple myeloma [10]
Coordinated regulation and 
codistribution in mammary 
tumor cells and epithelial-
mesenchymal transition [22-
25]
β-Catenin responsive 
progenitor cells depend on 
Sdc1 [27,28]
c-met Transmembrane tyrosine 
kinase receptor for 
hepatocyte growth factor
c-met pathway modulates 
cell dissociation and motility, 
protease overexpression and 
stimulates angiogenesis 
[11,12]
Expression associated with 
poor outcome in patients 
with (axillary) lymph node 
negative breast cancer 
[15,47,70]
Negative prognostic factor in 
breast cancer [71,72]
Not applicable Correlation with abnormal β-
catenin expression suggests 
downregulation of E-cad/β-
catenin by c-met [73]
E-cad Epithelial calcium-dependent 
cell adhesion molecule
Ensures structural integrity, 
and contact inhibition of 
epithelia [21]
Expression changes during 
epithelial-mesenchymal 
transition [40]
Involved in β-catenin-
mediated signalling [20]
Membranous staining is 
independent predictor for 
disease-free survival in 
lobular breast cancer [44]
Loss of expression is 
associated with negative ER 
status, high histological 
grade, metastasis and poor 
prognosis in breast cancer 
[43,45,46,74,75]
E-cad is used to distinguish 
ductal from lobular neopasia 
[18,19]
(See Sdc1) Not applicable
aSelected examples are given, along with references. E-cad, E-cadherin; ER, oestrogen receptor; Sdc, syndecan.Available online http://breast-cancer-research.com/content/9/1/R8
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In the present study we evaluated coexpression of the three
functionally linked prognostic factors, namely Sdc1, E-cad and
c-met, in ductal carcinoma in situ (DCIS) of the breast by sem-
iquantitative immunohistochemistry of a tissue microarray con-
taining tumour specimens from 200 patients. We recently
showed that several proangiogenic factors, including fibrob-
last growth factor receptor (FGFR)-1, vascular endothelial
growth factor (VEGF)-C, its receptor Flt-4, and the endothelin
A receptor (ETAR), are highly expressed in DCIS, suggesting
that  in situ carcinomas can induce angiogenesis and lym-
phangiogenesis [29]. Although expression of endothelin and
VEGF receptors was previously believed to be largely
restricted to the vascular endothelium, these receptors have
also been detected in breast cancer cells, suggesting an auto-
crine effect of their ligands on tumour cells [29-31]. Because
Sdc1 and c-met modulate angiogenesis in vivo
[2,4,12,32,33], we determined the association of these mole-
cules with markers of angiogenesis and lymphangiogenesis in
DCIS. Moreover, we characterized the coexpression of Sdc1,
E-cad and c-met in three differently aggressive human breast
cancer cell lines by RT-PCR and by confocal immunofluores-
cence microscopy. The aim of the study was to determine
whether coexpression of the functionally linked molecular
markers Sdc1, E-cad and c-met may constitute a novel angio-
genesis-associated molecular marker signature in DCIS.
Materials and methods
Cell culture and confocal immunofluorescence 
microscopy
The human breast cancer cell lines MCF-7 and MDA-MB468
were from our cell culture collection [34]. MCF-7 cells were
cultured in RPMI-1640 medium (Gibco, Karlsruhe, Germany)
supplemented with 10% foetal calf serum (PAA, Cölbe, Ger-
many) and 2 mmol/l L-glutamine. MDA-MB231 (CLS Cell
Lines Service, Eppelheim, Germany) and MDA-MB468 cells
were maintained in DMEM (Dulbecco's modified Eagle
medium) high-glucose medium (Invitrogen, Karlsruhe, Ger-
many) supplemented with 1% L-glutamine, 1% penicillin-
streptomycin and 10% foetal calf serum at 7.5% carbon diox-
ide. For immunocytochemistry, cells were grown to 80% con-
fluence in eight-well chamber slides (Corning Costar,
Wiesbaden, Germany), fixed with ice-cold methanol, and sub-
jected to immunostaining as follows. After a 30 min blocking
step with phosphate-buffered saline (PBS) containing 10%
goat serum (DAKO, Glostrup Denmark), the slides were
washed with PBS, and the following primary antibodies were
used in an overnight incubation at 4°C at a dilution of 1:100 in
PBS/1% bovine serum albumin: mouse anti-syndecan-1
(clone BB4; Serotec, Duesseldorf, Germany), rabbit anti-c-
met (Santa Cruz, Santa Cruz, CA, USA), and mouse anti-E-
cadherin (BD Transduction Laboratories, San Diego, CA,
USA). The slides were washed three times for 5 min with PBS
and incubated with AlexaFluor 546-conjugated goat-anti-
mouse IgG (Invitrogen) and AlexaFluor 488 conjugated don-
key-anti-rabbit IgG (Invitrogen) secondary antibodies in PBS/
1% bovine serum albumin at a dilution of 1:600 at room tem-
perature for 30 min. Samples that were incubated without a
primary antibody served as controls. Slides were washed
three times for 5 min with PBS and mounted using VectaSh-
ield (Vector Labs, Burlingame, CA, USA). Laser scanning
microscopy was performed using a Leica TCS SL confocal
microscope (Leica, Bensheim, Germany).
RT-PCR analysis
For RT-PCR analysis, total cellular RNA was prepared from
MCF-7, MDA-MB468, and MDA-MB231 cells using the RNe-
asy Mini kit (Qiagen, Hilden, Germany) in the presence of
RNAse-free DNAse. Total RNA 1 μg was reverse transcribed
using the Advantage RT-for-PCR Kit (BD Clontech, Heidel-
berg, Germany) and amplified in a BioMetra PCR reactor
(BioMetra, Göttingen, Germany). A DNA fragment corre-
sponding to base pairs 1233–1303 of human Sdc-1 mRNA
(accession # NM_001006946.1) was amplified using the
primers 5'-AGGACGAAGGCAGCTACTCCT-3' and 5'-TTT-
GGTGGGCTTCTGGTAGG-3' and the following amplifica-
tion cycle: 94°C for 4 min; 27 cycles of 94°C for 30 s, 60°C
for 30 s and 72°C for 30 s; and 72°C for 5 min. The primers
5'-TGGGTTATTCCTCCCATCAG-3' and 5'-TTTGTCAG-
GGAGCTCAGGAT-3' were used to amplify a PCR fragment
corresponding to base pairs 590–1066 of human E-cad
(accession # NM_004360.2) and the following amplification
cycle: 94°C for 5 min; 25 cycles of 94°C for 60 s, 60°C for 60
s, 72°C for 60 s; and 72°C for 10 min. Using the same ampli-
fication protocol, the primers 5'-TTCGGGTTGTAGGAGTCT-
TCT-3' and 5'-GGTTGCTGATTTTGGTCTTGC-3' were used
to amplify base pairs 3844–4105 of the human c-met mRNA
(accession # NM_000245.2). The housekeeping gene β-actin
was used as an internal control and amplified using the prim-
ers 5'-CAAAGACCTGTACGCCAACAC-3' and 5'-CAT-
ACTCCTGCTTGCTGATCC-3', corresponding to base pairs
943–1220 of human β-actin (accession # NM_001101) and
the following amplification cycle: 95°C for 3 min; 18 cycles of
95°C for 1 min, 56°C for 1 min and 72°C for 1 min; and 72°C
for 10 min.
PCR products were subjected to gel electrophoresis on 1.5%
agarose gels. After ethidium bromide staining, DNA bands
were photographed under UV illumination using a BioDoc
Analyze system (Biometra). Scanned bands were analyzed
using the Image J software (NIH, Bethesda, MA, USA) and sig-
nal intensities were normalized for actin expression.
Patients and tumour samples
To study expression and interrelation of c-met, Sdc1, and E-
cad in preinvasive breast cancer, tissue samples from 200
patients with DCIS were analyzed, with 96 patients exhibiting
a pure DCIS and 104 patients showing association of the
DCIS with an invasive breast carcinoma. The median age of
patients was 59 years (range 18–94 years). Informed consent
was obtained from the patients, and the study was carried outBreast Cancer Research    Vol 9 No 1    Götte et al.
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in compliance with the Helsinki Declaration. The criteria pro-
posed by Holland and coworkers [35], which consider nuclear
grading and architectural differentiation (cellular polarization),
were applied to classify all cases, resulting in gradings of low
(n = 54), intermediate (n = 49) and high (n = 94). Based on
these criteria, cases were finally classified as high-grade DCIS
or non-high-grade DCIS (low and intermediate grade). All tis-
sue samples were routinely paraformaldehyde fixed, paraffin
embedded and archived at the Gerhard-Domagk Institute of
Pathology, Münster University Hospital, Münster, Germany.
To allow permit simultaneous immunohistochemical staining of
tissue samples using identical staining conditions, tissue
microarrays (TMAs) were constructed from donor tissue
blocks as described previously [36]. Following evaluation of
haematoxylin and eosin stained microscope slides, at least
four morphologically representative regions of each donor
block were selected, and a TMA (2 cm × 3.5 cm) containing
four to eight core specimens for each DCIS patient was
assembled with a manual tissue arrayer (Beecher Instruments,
Silver Springs, MD, USA) equipped with a 0.6 mm punch nee-
dle. The presence of DCIS in the TMA samples was verified on
haematoxylin and eosin stained sections by a pathologist. Lob-
ular carcinoma in situ (LCIS), defined by its distinctive histo-
logical appearance (characterized by small cells of low nuclear
grade that fill and expand lobules without penetration of the
basement membrane), was not included in the DCIS TMA. In
cases of DCIS with a coexistent invasive carcinoma, only
DCIS was included in the TMA sections because the invasive
component was not available for analysis.
Immunohistochemistry of TMAs
Consecutive 3 μm sections were cut from the TMA blocks and
placed on poly-L-lysine coated coverslips. The dried cover-
slips were subsequently de-parrafinized, rehydrated and sub-
jected to antigen retrieval by autoclaving in citrate buffer (pH
6.0; DAKO) or microwave treatment, as previously described
[29]. After blocking of nonspecific binding, the sections were
incubated with the following primary antibodies (specific for
human target proteins): mouse anti-syndecan-1 (clone BB4,
Serotec; 1:100), rabbit anti-c-met (Santa Cruz; 1:100), mouse
anti-E-cadherin (BD Transduction Laboratories; 1:100), rabbit
anti-VEGF-A (Santa Cruz; 1:15), rabbit-anti-VEGF-C (Santa
Cruz; 1:25), rabbit anti-Flt-1 (Santa Cruz; 1:400), rabbit anti-
KDR (Santa Cruz; 1:400), rabbit anti-Flt-4 (Santa Cruz;
1:400), rabbit anti-bFGF (basic FGF; Santa Cruz; 1:2000),
rabbit anti-FGFR1 (Santa Cruz; 1:400), mouse-anti-ET-1
(endothelin-1; Affinity Bioreagents, Golden, CO, USA; 1:500),
sheep anti-ETAR (ETAR; Alexis, Lausen, Switzerland; 1:800),
sheep anti-ETBR (Alexis; 1:800). Oestrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth fac-
tor receptor (HER)2 were detected using standard immuno-
histochemical methods, as described previously [37]. As
negative controls, the first antibody was either omitted or iso-
type-specific control IgGs (monoclonal antibodies) or nonim-
mune rabbit IgG (polyclonal antibodies) diluted to the same
concentration as the first antibody were used. Following wash-
ing steps with PBS (three times for 5 min), the primary anti-
bodies were detected using either the DAKO EnVision system
(rabbit/mouse) with the Nova Red (Vector Labs) substrate
(Sdc1, c-met and E-cad), APAAP (bFGF, Flt-1, KDR and
FGFR1) or a labelled streptavidin-horseradish peroxidase
method. For more details on retrieval techniques and incuba-
tions, the reader is referred to the report by Wülfing and cow-
orkers [29].
Slide scoring and statistical analysis
Semiquantitative analysis of staining results of 902 individual
tissue array cores was performed by two investigators in a
blinded manner without knowledge of the clinical data for the
corresponding cases. Only core specimens that were con-
firmed to contain DCIS were included in the analysis. Conse-
quently, not all cases could be analyzed for each individual
marker. Sdc1, c-met and E-cad exhibited predominantly epi-
thelial staining, which for the most part localized to the cell
membrane. Additional cytoplasmic staining was frequently
observed (for example, see Figure 3). Intensity of the immunos-
taining was scored semiquantitatively on an arbitrary four-
tiered scale (negative = 0, weak = 1+, moderate = 2+ and
strong = 3+). Grade 0 represented cases with no detectable
immunostaining of tumour cells, whereas cases graded as 1+
exhibited weak staining of the majority of tumour cells. Tissue
sections with a moderate or strong staining intensity were
scored as 2+ or 3+, respectively. In the final score, samples
with a moderate or strong immunostaining (score 2+ and 3+)
were defined as 'positive', and samples with a weak or absent
immunostaining as 'negative'.
An analogous scoring system was used to evaluate FGFR1,
ET-1, ETAR and ETBR (cytoplasmic immunostaining), VEGF-C
and Flt-4 (cytoplasmic and nuclear immunostaining), and KDR
expression (cytoplasmic with occasional membraneous stain-
ing) [36]. Similarly, HER2 staining was scored on a scale rang-
ing from 0 (absent) to 3+ (maximum cytomembranous
staining), with a score above 2+ considered HER2 positive.
The cytoplasmic immunostaining intensity of Flt-1 was classi-
fied on a three-tiered scale from 0 (negative) to 2+ (moderate),
with cases scored as 1+ and 2+ considered Flt-1 'positive'.
Expression of bFGF and VEGF-A was characterized as a neg-
ative or positive reaction according to both the percentage of
stained tumour cells and the immunostaining intensity. When
more than 10% of the tumour cells exhibited moderate or
strong cytoplasmic immunoreaction, samples were defined as
'positive' [31]. ER and PR status were defined 'positive' when
more than 10% nuclei stained positively.
Staining results for c-met, Sdc1 and E-cad were correlated
with each other and with the expression of angiogenic and
lymphangiogenic markers, as well as with ER, PR and HER2
status. In addition, expression of c-met, Sdc1 and E-cad wasAvailable online http://breast-cancer-research.com/content/9/1/R8
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correlated with the type of DCIS (pure versus coexistent) and
nuclear grading. Correlations were tested for statistical signif-
icance by cross tables, applying Pearson's χ2 test and Fishers'
exact test using SPSS version 10.0 for Windows (SPSS Inc.,
Chicago, IL, USA). The Bonferroni adjustment was calculated
as αadj = 1 - (1 - α)1/n, with n = 17 tests [38].
Results
Colocalization and expression of Sdc1, E-cad and c-met 
in human breast cancer cell lines
To characterize the interrelationship between the molecular
markers investigated in this study, we performed confocal
immunofluorescence microscopy colocalization experiments
of c-met with Sdc1 and E-cad in human breast cancer cell
lines. MCF-7, MDA-MB468 and MDA-MB231 cells, repre-
senting breast cancer cell lines of increasing dedifferentiation
and metastatic capacity [39], were stained with antibodies
specific for c-met, Sdc1 and E-cad (Figure 1). Sdc1 immuno-
reactivity was primarily located at the cell surface. In MDA-
MB468 cells, a fuzzy membranous staining pattern of Sdc1
was observed, possibly indicating alterations in cell-cell con-
tacts. Similar to Sdc1, E-cad staining localized to the plasma
membrane. However, an inverse correlation of E-cad expres-
sion with the degree of tumour cell de-differentiation was
observed, because membraneous staining was almost absent
Figure 1
Immunolocalization of Sdc1, E-cad and c-met in human breast cancer  cell lines Immunolocalization of Sdc1, E-cad and c-met in human breast cancer 
cell lines. The human breast cancer cell lines MCF-7, MDA-MB468 and 
MDA-MB231 were stained with antibodies specific for c-met (green flu-
orescent secondary antibody) and Sdc1 or E-cad (red secondary anti-
bodies), and observed by confocal immunofluorescence microscopy. 
Yellow staining denotes colocalization of c-met with Sdc1 or E-cad. E-
cad, E-cadherin; Sdc, syndecan.
Figure 2
RT-PCR analysis of Sdc1, E-cad and c-met in human breast cancer cell  lines RT-PCR analysis of Sdc1, E-cad and c-met in human breast cancer cell 
lines. RNA was prepared from MCF-7, MDA-MB468 and MDA-MB231 
breast cancer cells; mRNA was reverse transcribed and used as a tem-
plate for PCR amplification of Sdc1, E-cad and c-met (as described in 
Materials and methods section). (a) PCR band intensities were normal-
ized for actin expression and the data from three independent experi-
ments were analyzed using the paired Student's t-test. (b) *P < 0.01 
(Sdc1: MDA-MB468 versus MDA-MB231; E-cad and c-met: MCF-7 
versus MDA-MB231, MCF-7 versus MDA-MB468 and MDA-MB468 
versus MDA-MB231). AU, arbitrary units; E-cad, E-cadherin; RT-PCR, 
reverse transcription polymerase chain reaction; Sdc, syndecan.Breast Cancer Research    Vol 9 No 1    Götte et al.
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in MDA-MB231 cells. A punctate staining pattern was exhib-
ited by c-met. In MCF-7 cells, c-met partially colocalized with
Sdc1 and E-cad. The degree of colocalization appeared to be
higher in MCF-7 cells than in MDA-MB468 cells. In MDA-
MB231 cells, colocalization with c-met could not be assessed
because of the low level of E-cad expression.
We next compared expression of Sdc1, E-cad and c-met at
the mRNA level by semiquantitative RT-PCR (Figure 2). Similar
levels of Sdc1 expression were observed in MCF-7 and MDA-
MB468 cells, but Sdc1 mRNA expression was significantly
lower (P < 0.001) in MDA-MB231 cells than in MDA-MB468
cells. With increasing de-differentiation and higher metastatic
potential (MCF-7 < MDA-MB468 < MDA-MB231), a signifi-
cant decrease in E-cad mRNA expression was observed (Fig-
ure 2b). Of note, expression levels of c-met exhibited an
inverse relation, with the highest expression in MDA-MB231
cells (Figure 2).
Immunohistochemical staining of Sdc1, E-cad and c-met 
in DCIS
We next employed TMA technology to determine the expres-
sion of Sdc1, E-cad and c-met in 200 cases of DCIS of the
breast. Tumour cells exhibited variable expression of Sdc1,
ranging from weak to strong. Staining was predominantly
membranous but often additionally cytoplasmic. Stromal cells
and myoepithelial cells showed no immunoreactivity (Figure
3). For c-met there was weak to strong membrane bound and
additional cytoplasmic expression in stromal cells, and myoep-
ithelial cells remained negative (Figure 3). Expression of E-
cadherin was observed in almost all cases of DCIS, with the
majority exhibiting strong immunoreactivity. Staining in tumour
cells was membranous and cytoplasmic, whereas stroma and
myoepithelium remained negative (Figure 3).
Detailed staining results for all three markers in DCIS are listed
in Table 2. Based on a four-tiered scale, moderate to strong
positive staining of tumour cells was observed for Sdc1 in 108
out of 150 (72%), for c-met in 69 out of 142 (48.6%) and for
E-cad in 101 out of 149 (67.8%) evaluable DCIS samples.
We next investigated the interrelation of Sdc1, c-met and E-
cad expression. Expression of E-cad was significantly corre-
lated with expression of c-met (P = 0.004) and Sdc1 (P =
0.007; Table 3).
Correlation of Sdc1, c-met and E-cad expression with 
histopathological characteristics
A significant correlation was observed between expression of
c-met and HER2 (P = 0.044), and there was a trend toward
an association of HER2 with Sdc1 expression (P = 0.057;
Table 3). No significant correlation of high-to-moderate c-met,
Sdc-1 and E-cad expression with ER and PR status or high-
grade DCIS [35] was observed (Table 3). Expression of c-met
(P < 0.001) and Sdc1 (P = 0.037) was significantly more fre-
quent in the subgroup of pure DCIS than in the subgroup of
DCIS with a coexistent invasive carcinoma (Table 4). These
differences were not due to an unequal distribution of his-
topathologic or clinical features, because analysis of the distri-
bution of patients' age, ER, PR and HER2 status, and nuclear
grading revealed no statistically significant differences
between three subgroups (data not shown).
Correlation of c-met, Sdc1 and E-cad expression with 
angiogenic and lymphangiogenic factors
Expression of four ligand-receptor pairs known to play a role in
angiogenesis and lymphangiogenesis was analyzed to test for
a potential association of c-met, Sdc1 and E-cad expression
with such angiogenic and lymphangiogenic factors: VEGF-A
and its receptors Flt-1 and KDR; bFGF and its receptor
FGFR1; the endothelin axis, comprised of ET-1 and its recep-
Figure 3
Representative immunohistochemical staining patterns for E-cad, c- met, and Sdc1 in DCIS Representative immunohistochemical staining patterns for E-cad, c-
met, and Sdc1 in DCIS. Examples for presence (positive) and absence 
(negative) of marker expression are shown. DCIS, ductal carcinoma in 
situ; E-cad, E-cadherin; Sdc, syndecan.
Table 2
Immunohistochemical analysis of Sdc1, c-met and E-cad 
expression in DCIS of the breast
Score c-met (n = 142) E-cad (n = 149) Sdc1 (n = 150)
0 10 (7) 11 (7.4) 4 (2.7)
1 63 (44.4) 37 (24.8) 38 (25.3)
2 51 (35.9) 89 (59.7) 103 (68.7)
3 18 (12.7) 12 (8.1) 5 (3.3)
Negative (score 0–1) 73(51.4) 48 (32.2) 42 (28)
Positive (score 2–3) 69 (48.6) 101 (67.8) 108 (72)
Values are expressed as number of evaluable tissue specimens (%). 
DCIS, ductal carcinoma in situ; E-cad, E-cadherin; Sdc, syndecan.Available online http://breast-cancer-research.com/content/9/1/R8
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tors ETAR and ETBR; and the lymphangiogenic factor VEGF-C
and its receptor Flt-4 (Table 5).
VEGF-A exhibited faint to moderate cytoplasmic staining of
tumour cells. Positive staining was also observed in myoepi-
thelial cells, whereas normal glandular epithelial cells as well
as stromal and connective tissue were mostly VEGF-A nega-
tive. KDR staining presented as strong cytoplasmic staining.
Normal glandular epithelial cells stained positive for KDR,
whereas stroma and connective tissue exhibited no staining.
Flt-1 immunoreactivity presented as a granular cytoplasmic
staining of tumour cells and of the peritumoural stroma. Normal
glandular epithelial cells stained negative for Flt-1.
bFGF staining of tumour cells was predominantly nuclear and
occasionally cytoplasmic. Although the stroma was bFGF neg-
ative, positive staining of normal glandular epithelial cells was
frequently observed. Tumor cells exhibited strong cytoplasmic
staining for FGFR1, whereas normal glandular cells were mod-
erately positive, and the majority of stromal cells were weakly
positive.
Expression of ET-1, ETAR and ETBR presented as positive
cytoplasmic staining of tumour cells, and a faint additional stro-
mal staining was observed in some ET-1 positive cases. Nor-
mal glandular epithelial cells were mostly negative for markers
of the endothelin axis.
VEGF-C staining presented as strong cytoplasmic staining of
tumour cells, whereas normal breast epithelium was largely
VEGF-C negative, as was the stroma and connective tissue.
Tumor cells stained strongly positive for Flt-4, and positive
staining was also frequently observed in normal glandular epi-
thelium. In contrast, no Flt-4 staining was detected in the
stroma and connective tissues.
A highly significant correlation of c-met expression with ETAR
and ETBR was found; 92.6% of c-met positive DCIS versus
56.7% of c-met negative DCIS stained positive for ETAR (P <
0.001), and 57.4% of c-met positive tumours versus 23.4% of
c-met negative tumours stained positive for ETBR (P < 0.001).
Furthermore, c-met expression exhibited a significant positive
correlation with expression of VEGF-A (P  = 0.040) and
FGFR1 (P = 0.028; Table 5).
Similar to c-met, E-cad expression was significantly correlated
with ETAR expression (P < 0.001). In addition, we observed a
significant correlation of E-cad expression with positive stain-
ing for VEGF-A (P = 0.005) and VEGF-C (P = 0.048).
Sdc1 exhibited a trend toward correlation with lymphang-
iogenic factors (VEGF-C, P = 0.061; Flt-4, P = 0.071; Table
5).
Discussion
In this study we characterized coexpression of the functionally
linked prognostic markers Sdc1, E-cad and c-met in 200
DCIS using TMA technology and in different human breast
cancer cell lines. Our initial objective was to identify a group of
functionally interrelated markers that have prognostic signifi-
cance in breast cancer. In this regard we observed significant
correlations between expression levels for the markers c-met,
Sdc1 and E-cad in DCIS. The markers c-met and Sdc1 were
significantly more frequently expressed in pure DCIS than in
DCIS with a coexistent invasive carcinoma. In the case of
Sdc1, this finding may indicate downregulation during epithe-
Table 3
Interrelation of c-met, E-cad and Sdc1 expression in DCIS and correlation with histopathological characteristics
c-met E-cad Sdc1
Negative 
(n = 73)
Positive 
(n = 69)
P Negative 
(n = 48)
Positive 
(n = 101)
P Negative 
(n = 42)
Positive 
(n = 105)
P
c-met positive 0.0% 100.0% 30.8% 58.8% 0.004 38.2% 56.3% 0.071
E-cad positive 56.5% 80.6% 0.004 0.0% 100.0% 51.4% 76.0% 0.007
Sdc1 positive 66.7% 80.6% 0.071 58.5% 80.9% 0.007 0.0% 100.0%
High grade DCIS 47.2% 48.5% 0.877 47.9% 47.5% 0.960 37.5% 49.5% 0.193
ER positive 25.4% 31.3% 0.463 20.0% 31.5% 0.176 37.1% 26.0% 0.251
PR positive 33.9% 37.9% 0.643 37.8% 33.7% 0.655 40.0% 31.6% 0.368
ErbB2 positive 12.5% 27.3% 0.044 23.5% 23.9% 0.964 11.8% 28.0% 0.057
DCIS, ductal carcinoma in situ; E-cad, E-cadherin; ER, oestrogen receptor; PR, progesterone receptor; Sdc, syndecan.
Table 4
Expression of c-met, Sdc1 and E-cad in the subgroups of pure 
DCIS and DCIS with coexistent invasive carcinoma
Molecular marker Pure DCIS Coexistent DCIS P
Sdc1 59/74 (79.7%) 49/76 (64.5%) 0.037
c-met 47/72 (65.3%) 22/70 (31.4%) <0.001
E-cad 56/76 (73.7%) 45/73 (61.6%) 0.116
DCIS, ductal carcinoma in situ; E-cad, E-cadherin; Sdc, syndecan.Breast Cancer Research    Vol 9 No 1    Götte et al.
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lial-mesenchymal transition [40,41], which has been
demonstrated in mammary epithelial cells in vitro [23,24] and
during development [22]. Regarding the association between
the expression pattern of Sdc1, E-cad and c-met with disease
progression, future studies could investigate the correlation
with expression for coexisting DCIS and invasive carcinoma.
However, based on our cell culture data and on current knowl-
edge on the prognostic value and biological function of the
markers (see Table 1), we speculate that a reduction in E-cad
expression and an upregulation of Sdc1 expression may occur
in the invasive component of mixed lesions. In the case of c-
met, our finding that c-met expression is highest in MDA-
MB231 cells, and exhibits a positive correlation with other fea-
tures of aggressiveness such as HER2 overexpression seem-
ingly contradicts our observation that c-met expression is
higher in pure DCIS than in DCIS associated with invasive
cancer. We recently observed significantly increased expres-
sion of prognostically unfavourable proangiogenic factors in
pure DCIS compared with coexistent DCIS [29]. This is con-
sistent with findings reported by Teo and coworkers [42], who
described different vascular density and phenotypes in pure
versus coexistent DCIS. Therefore, the preferential associa-
tion of c-met expression with pure DCIS may be indicative of
the increased angiogenic activity in pure DCIS [11,29].
The metastatic origin of the investigated human breast cancer
cell lines [39] has inherent limitations with respect to a direct
comparison of marker expression in DCIS tissue. However, the
positive correlation of c-met, Sdc1 and E-cad in an early stage
of tumour progression at the tissue level was largely supported
by our colocalization studies in these cell lines, in which partial
colocalization was observed between c-met and Sdc1 and E-
cad, respectively, in the less aggressive MCF-7 and MDA-
MB468 cell lines. In addition, Sdc1 and E-cad exhibited a sim-
ilar cell surface distribution in these cells. Moreover, progres-
sive loss of E-cad expression and a progressive increase in c-
met expression were observed with increasing de-differentia-
tion and higher metastatic potential (MCF-7 < MDA-MB468 <
MDA-MB231) of the breast cancer cell lines at the mRNA
level.
These findings are similar to the expression patterns of E-cad
and c-met observed in clinical studies. Reduced expression of
E-cad in breast carcinoma is associated with shortened dis-
ease-free survival and high histological grade [43-46],
whereas high expression of c-met is associated with more
aggressive disease and decreased disease-free survival in
node-negative breast cancer [15,47] (see Table 1). In addi-
tion, coordinated overexpression of c-met and the oncogene
RON is observed in MBA-MB231 but not in MCF-7 cells [15].
Our observation of a synchronous downregulation of E-cad
and Sdc1 mRNA in highly aggressive MDA-MB231 cells is in
accordance with previous in vitro experiments on mammary
epithelial cells [23,24]. Expression of Sdc1 can be regulated
at the post-transcriptional level [48,49], which may explain the
strong Sdc1 protein expression observed by confocal immun-
ofluorescence microscopy in MDA-MB231 cells (Figure 1).
The heterogeneity in Sdc1 and E-cad coexpression in breast
cancer cell lines of different degrees of de-differentiation dem-
onstrates that the concept of synchronous regulation of Sdc1
and E-cad in epithelial cells [23,24] cannot be fully adapted to
breast cancer. Our data suggest that the degree of coexpres-
sion is higher in breast cells that exhibit a more benign pheno-
type, such as DCIS, whereas coexpression may be lost in
more advanced stages of tumour progression. These findings
could help to explain why no correlation was found between E-
cad and Sdc1 expression in a patient collective containing
ductal invasive, lobular and tubular breast cancer tissues [8],
Table 5
Correlation of c-met, Sdc1 and E-cad expression with angiogenic and lymphangiogenic factors
c-met E-cad Sdc1
Negative (n = 73) Positive (n = 69) P Negative (n = 48) Positive (n = 101) P Negative (n = 42) Positive (n = 105) P
VEGF-A 36.2% 53.8% 0.040 26.2% 52.0% 0.005 55% 41.6% 0.149
Flt-1 18.6% 7.7% 0.063 14.3% 11.5% 0.642 12.8% 12.5% 0.959
KDR 48.4% 63.1% 0.094 47.4% 56.4% 0.347 45.7% 58.3% 0.198
VEGF-C 84.5% 94.1% 0.068 80.4% 91.8% 0.048 80.5% 91.5% 0.061
Flt-4 92.9% 98.6% 0.099 95.1% 97.0% 0.584 90.0% 97.2% 0.071
ET-1 47.7% 59.7% 0.176 52.4% 48.9% 0.709 47.4% 51.6% 0.661
ETAR 56.7% 92.6% <0.001 53.8% 86.9% <0.001 70.3% 79.0% 0.277
ETBR 23.4% 57.4% <0.001 30.8% 43.3% 0.177 31.6% 47.0% 0.102
BFGF 17.4% 11.9% 0.394 10.0% 13.4% 0.583 18.9% 11.4% 0.250
FGFR1 89.1% 98.4% 0.028 92.3% 95.9% 0.394 91.4% 96.0% 0.287
bFGF, basic fibroblast growth factor; E-cad, E-cadherin; ET, endothelin; ETA/BR, endothelin A/B receptor; FGFR, fibroblast growth factor 
receptor; Sdc, syndecan; VEGF, vascular endothelial growth factor.Available online http://breast-cancer-research.com/content/9/1/R8
Page 9 of 12
(page number not for citation purposes)
whereas a correlation was found in our more uniform DCIS
collective.
We observed no significant association of c-met, E-cad and
Sdc-1 expression with hormone receptor status in DCIS. In
patient collectives including more advanced stages of breast
cancer progression, clinical and experimental data suggest a
possible link between loss of E-cad expression and ER-nega-
tive status [20,43,50]. Moreover, recent studies have linked
Sdc1 expression to an aggressive, ER-negative breast carci-
noma subtype [6-8]. In order to distinguish between low and
high expression levels of possibly synchronously regulated
Sdc1 and E-cad, both low expression and absence of staining
for the markers investigated were scored as 'negative'.
Although application of this scoring method was necessary to
detect synchronous coregulation of marker expression, it
might have lead to failure to demonstrate significant associa-
tions of E-cad expression with hormone receptor status and
grade of DCIS in the present study. Although it may occasion-
ally be difficult to distinguish between DCIS and LCIS in cases
where LCIS may involve extralobular ducts, we can largely
exclude the possibility that the analyzed DCIS cases were
erroneously scored as LCIS (see Materials and methods,
above).
We found a significant correlation between HER2 and c-met
expression. This correlation may be of functional importance,
because both molecules are tyrosine kinase receptors that
promote cell proliferation [11,51]. Of note, Khoury and cow-
orkers [51] recently demonstrated that HGF-mediated c-met
signalling in the presence of constitutively active HER2 leads
to a downregulation of E-cad and promotes epithelial-mesen-
chymal transition in MDCK cells. Thus, signalling downstream
of the c-met receptor synergizes with HER2 to enhance a
malignant phenotype. In a similar manner, additional receptors
could contribute to this synergism in signalling, and our finding
of c-met correlating with FGFR1 expression does support this
view. Moreover, this hypothesis is supported by a study on the
expression of c-met and the tyrosine kinase receptor RON in
node-negative breast cancer patients [15]. Ten-year disease-
free survival was significantly decreased in patients with
tumours expressing only one of the two markers, and it was
even worse in patients with RON-positive/c-met-positive
tumours. Because Sdc1 is an established coreceptor for sev-
eral receptor tyrosine kinases, including FGFR1 [1,3] and c-
met [10], it could also contribute to synergistic signalling. We
observed a trend toward a correlation of Sdc1 and HER2
expression in DCIS (P = 0.057). This is in accordance with the
study conducted by Barbareschi and coworkers [6], which
demonstrated positive correlation of Sdc1 and HER2 in a col-
lective of 254 invasive breast carcinomas. In accordance with
its role as a signalling coreceptor, a recent study conducted in
207 breast cancer patients demonstrated a significant
association of Sdc1 overexpression with the Ki67 proliferation
index [8].
In DCIS, an increase in periductal blood vessels has been cor-
related with recurrence of invasive disease [52],
demonstrating the relevance of angiogenesis to tumour pro-
gression. Expression of the angiogenic factor VEGF-A in
tumour cells from patients with DCIS was shown to correlate
with the degree of angiogenesis [53]. In the present study, we
found a significant correlation of both c-met and E-cad with
VEGF-A expression in DCIS. In addition, c-met expression
exhibited a negative correlation with Flt-1 expression; Flt-1 is a
negative regulator of VEGF availability, which is regarded as
an antiangiogenic receptor. Our findings constitute the first
characterization of a proangiogenic role for c-met, Sdc1 and
E-cad in DCIS, but they are in accordance with published work
on the biological role of these molecules. Ribozyme targeting
of c-met in mammary cancer cells reduced mammary cancer
and tumour-associated angiogenesis in a xenograft model
[12]. In addition, the HGF-antagonist NK4 inhibits c-met sig-
nalling and angiogenesis in vitro [32] and reduces intratu-
moural microvessel density in a hepatocellular carcinoma
xenograft model [54]. Sdc1 acts as a coreceptor for several
angiogenic and growth factors, including multiple VEGF iso-
forms and bFGF [1,3]. In vivo, we recently demonstrated
increased corneal angiogenesis in Sdc-1 deficient mice and
the formation of abnormally dilated blood vessels in skin
wounds of Sdc-1 overexpressing mice, indicating a regulatory
role for Sdc1 in angiogenesis [2,4]. Moreover, in a nude
mouse xenograft model, coinjection of MDA-MB-231 breast
cancer cells with Sdc-1 overexpressing and mock-transfected
mouse fibroblasts resulted in significantly elevated microves-
sel density and a larger vessel area in tumours containing
Sdc1 overexpressing stroma cells [33]. A TMA analysis of 207
human breast cancer samples by the same authors revealed
that stromal Sdc1 expression correlated with vessel density
and total vessel area, demonstrating a role for Sdc1 in breast
tumour angiogenesis.
Although we observed a trend toward an association of Sdc1
expression with markers of lymphangiogenesis, we could not
demonstrate a statistically significant correlation of Sdc1
expression and proangiogenic markers in DCIS (Table 5). This
finding may suggest that the angiogenesis-associated func-
tions of Sdc1 primarily contribute to more advanced stages of
tumour progression. We have recently demonstrated that
VEGF-C and Flt-4, which are established mediators of lym-
phangiogenesis [55,56], were expressed in the tumour cells of
a large proportion (88% to 95%) of DCIS specimens [29]. In
the present study, we found a significant association of E-cad
with VEGF-C expression (P = 0.048). Althuogh very little is
known about the role of E-cad in lymphangiogenesis, by virtue
of its biological role an involvement in this process could easily
be envisaged. Moreover, the correlations of VEGF-A/C with E-
cad and of VEGF-A with c-met could be a sign of an ang-
iogenic stimulation of the stroma by the tumour cells [57]. Fur-
thermore, the preferential expression of Sdc1 and c-met in
pure versus coexistent DCIS parallels the significantly moreBreast Cancer Research    Vol 9 No 1    Götte et al.
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common expression of proangiogenic factors in pure versus
coexistent DCIS [29].
ET-1 and its G-protein-coupled receptors ETAR and ETBR (the
endothelin axis) are overexpressed in breast carcinomas, and
influence angiogenesis, tumourigenesis and tumour progres-
sion [34,36,58]. Moreover, we previously demonstrated over-
expression of the ET axis in DCIS and observed an association
with different angiogenic and lymphangiogenic factors [29].
An important novel finding of the present study is the highly
significant association of c-met and E-cad expression with ET
receptor expression. Similar to ETAR [34], c-met expression is
upregulated by hypoxia [59], thus promoting invasive growth
of tumour cells. In addition, the c-met ligand HGF has been
shown to inhibit ET-1 release in endothelial cells, indicating a
possible link between c-met mediated signalling and the ET
axis [60]. However, the coexpression of c-met and the ET
receptors may simply indicate an upregulation of parallel sig-
nalling pathways that utilize different upstream ligands and
converge intracellularly. Sdc1 and E-cad have been associ-
ated with epithelial-mesenchymal transition [22,40], and it has
recently been shown that ET-1 mediated signalling is required
during epithelial-mesenchymal transition in ovarian cancer pro-
gression [61,62]. In ovarian cancer [61,62] and melanoma
[63,64], activation of the ET axis results in downregulated E-
cad expression. In DCIS, coexpression of ET receptors, E-cad,
c-met and Sdc1 may constitute a specific expression signa-
ture indicative of the transition of an early stage to later stages
of tumour progression.
One possible caveat associated with the present study is the
large number of statistical tests that were performed (n = 17).
Although the statistical analysis employed in this study permits
easier comparison and interpretation of P values within the
context of the results from other studies, the reader must keep
in mind that some significant associations may be falsely
positive. Using a Bonferroni adjustment, the corrected signifi-
cance level for the tests employed in this study would be P <
0.003. However, although corrections for multiple compari-
sons on the one hand reduce the chances of making a type I
error, the chances of making a type II error are increased.
Moreover, the relevance of the null hypothesis underlying Bon-
ferroni adjustments has recently been questioned (see the
report by Perneger [38] for a discussion). Therefore, there
remains a lack of consensus within the scientific community
regarding whether corrections for multiple comparisons are
applicable.
Conclusion
In the present study we demonstrated coexpression of c-met,
Sdc1 and E-cad in DCIS. Of note, expression of c-met, Sdc1
and E-cad correlated with expression of angiogenic and
lymphangiogenic factors, including endothelin receptor
expression. It is tempting to speculate that this expression sig-
nature indicates a state of a parallel, synergistic activation of
multiple receptor pathways (receptor tyrosine kinases, G-pro-
tein-coupled receptors and nuclear transcription factors),
which vastly promote tumour cell proliferation and angiogen-
esis in the tumour stroma. Since these activation pathways rely
on different molecular mechanisms, therapeutic approaches
must take multiple targets into consideration. Inhibitors of tyro-
sine kinases, of the endothelin axis, of heparan sulphate-mod-
ulated signalling and of angiogenesis are currently being
evaluated in clinical trials or have already found their way into
cancer therapies [5,65-69]. Data from the present study may
help in the development of more efficient therapeutic
approaches in breast cancer, addressing the need to target
simultaneously multiple molecules that are relevant to this early
step of breast cancer progression.
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